Venaxis Inc. (APPY) climbs in the post-trade session after providing an update on its clinical and commercial activities, reporting in its 10-K that it continues to enroll patients into its ongoing clinical study of APPY1, and it anticipates completing the study and potentially filing with the FDA for regulatory clearance by year end. Read more on its Business Update Conference Call Here: Business Update Transcript. Shares +5% AH.
Venaxis Inc. (APPY) climbs in the post-trade session after providing an update on its clinical...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs